Location: Seattle
Synced from ClinicalTrials.gov · July 28, 2026
Clinical studies recruiting near Seattle
Studies with at least one listed site matching this
location on the public registry. Each page explains the study in plain
language, with locations and study-team contacts.
Clinicians: generate a
printable list for your patient →
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Phase 3 · Investigative Site US058 · Incyte Corporation · NCT06959225To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
Phase 3 · Biomed Testing Facility #BIO-20-98105 · Biomed Industries, Inc. · NCT06840496Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Speci
Phase 3 · University of Washington Fred Hutch Cancer Center · Corvus Pharmaceuticals, Inc. · NCT06561048A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Phase 1/Phase 2 · Fred Hutchinson Cancer Center- Site Number : 8400010 · Sanofi · NCT05584670Product Surveillance Registry
Phase N/A · Medtronic · NCT01524276Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Phase 2 · Pacific Northwest Airways - VA Puget Sound Healthcare System · Johns Hopkins University · NCT07059091Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplant
Phase 2 · Fred Hutchinson Cancer Research Center / Seattle Cancer Care · New York Blood Center · NCT01656603Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Phase 2 · Swedish Cancer Institute · Providence Health & Services · NCT06353997Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease
Phase 1 · Fred Hutch/University of Washington Cancer Consortium · Fred Hutchinson Cancer Center · NCT05067595Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance
Phase 2 · Fred Hutch/University of Washington Cancer Consortium · Fred Hutchinson Cancer Center · NCT07209371Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Meta
Phase 2 · Swedish Medical Center-First Hill · National Cancer Institute (NCI) · NCT06029270A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard
Phase N/A · Seattle Children's Home Health Company · Regeneron Pharmaceuticals · NCT06693531Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · Fred Hutch/University of Washington Cancer Consortium · Fred Hutchinson Cancer Center · NCT03779854HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Phase 2 · Fred Hutchinson Cancer Research Center · Children's Hospital Medical Center, Cincinnati · NCT02143830ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
NA · University of Washington · JenaValve Technology, Inc. · NCT06608823A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
Phase 2 · Bluefin Biomedicine, Inc. · NCT07105488Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · Virginia Mason Medical Center · National Cancer Institute (NCI) · NCT05987241A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
NA · University of Washington · University of Washington · NCT06411561TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Phase 1 · Fred Hutchinson Cancer Center · Shenzhen TargetRx Co., Ltd. · NCT06088888Spinal Cord Stimulation for Autonomic Recovery in Inpatient Rehabilitation After Acute SCI
NA · University of Washington · University of Washington · NCT06540859A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · Fred Hutch Cancer Center · Phanes Therapeutics · NCT05652686JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
Phase 2 · Swedish Medical Center · PPD Development, LP · NCT06701656A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Canc
Phase 3 · Fred Hutch Cancer Center Sloan Clinic 2 · Janssen Research & Development, LLC · NCT07225946Can Conventional ECG Technology Capture Fetal Cardiac Activity?
NA · University of Washington · University of Washington · NCT03111173Use of CereGate Therapy for Freezing of Gait in PD
NA · University of Washington · CereGate Inc. · NCT05292794HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Phase 1/Phase 2 · University of Washington/Fred Hutchinson Cancer Center · Hutchmed · NCT07396584RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Th
Phase N/A · Swedish Neuroscience Institute · Boston Scientific Corporation · NCT01719055Deep Brain Stimulation of Treatment-Resistant Bipolar Depression
NA · University of Washington · Wayne Goodman MD · NCT06599099Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Parti
Phase 2 · Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuro · Providence Health & Services · NCT06175000Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Phase N/A · Swedish Medical Center-Ballard Campus · ECOG-ACRIN Cancer Research Group · NCT06002828
Look up another city
Look up another condition